ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 54 filers reported holding ADC THERAPEUTICS SA in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,179 | -60.3% | 1,315 | -4.8% | 0.00% | – |
Q2 2023 | $2,971 | -98.1% | 1,382 | -98.3% | 0.00% | – |
Q1 2023 | $157,732 | -99.1% | 80,888 | -98.3% | 0.00% | -100.0% |
Q4 2022 | $17,869,261 | -51.7% | 4,653,453 | -39.4% | 0.00% | -50.0% |
Q3 2022 | $36,985,000 | -39.4% | 7,673,137 | -0.1% | 0.00% | -33.3% |
Q2 2022 | $61,065,000 | -45.9% | 7,681,046 | 0.0% | 0.01% | -33.3% |
Q1 2022 | $112,835,000 | -27.2% | 7,681,046 | +0.1% | 0.01% | -18.2% |
Q4 2021 | $154,988,000 | -25.6% | 7,672,673 | 0.0% | 0.01% | -35.3% |
Q3 2021 | $208,390,000 | +11.5% | 7,672,673 | 0.0% | 0.02% | +13.3% |
Q2 2021 | $186,830,000 | -1.4% | 7,672,673 | -1.1% | 0.02% | -6.2% |
Q1 2021 | $189,460,000 | -23.7% | 7,761,585 | 0.0% | 0.02% | -27.3% |
Q4 2020 | $248,448,000 | -1.8% | 7,761,585 | +1.2% | 0.02% | -15.4% |
Q3 2020 | $253,085,000 | +3.1% | 7,671,585 | +46.3% | 0.03% | -3.7% |
Q2 2020 | $245,483,000 | – | 5,244,231 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vantage Consulting Group Inc | 1,186,215 | $9,430,000 | 5.29% |
GCM Grosvenor Holdings, LLC | 1,298,012 | $10,319,000 | 2.33% |
Redmile Group, LLC | 7,512,029 | $59,721,000 | 2.28% |
MPM BioImpact LLC | 334,384 | $2,658,000 | 0.74% |
Indie Asset Partners, LLC | 93,989 | $747,000 | 0.66% |
Eventide Asset Management | 1,879,959 | $14,946,000 | 0.32% |
Walleye Capital LLC | 888,700 | $7,065,000 | 0.20% |
Endurant Capital Management LP | 58,967 | $469,000 | 0.16% |
HHLR ADVISORS, LTD. | 500,000 | $3,975,000 | 0.08% |
Matrix Capital Management Company, LP | 400,000 | $3,180,000 | 0.07% |